FibroScan-aspartate transaminase: A superior non-invasive model for diagnosing high-risk metabolic dysfunction-associated steatohepatitis

Figure 1 Flow diagram of patient selection process. NAFLD: Non-alcoholic fatty liver disease; MASLD: Metabolic dysfunction-associated steatotic liver disease; LSM: Liver stiffness measurement; CAP: Controlled attenuation parameter; MASH: Metabolic dysfunction-associated steatohepatitis; NAS: Non-alcoholic fatty liver disease activity score.

Figure 2 The distribution of seven non-invasive models based on high threshold criteria. A: The distribution of non-invasive models in the overall population; B: The distribution of non-invasive models in the subgroup population. MASH: Metabolic dysfunction-associated steatohepatitis; FAST: FibroScan-aspartate transaminase; FIB-4: Fibrosis-4; APRI: Aspartate transaminase to platelet ratio index; ARR: Aspartate transaminase to alanine transaminase ratio; GPR: Gamma-glutamyl transpeptidase to platelet ratio.

Figure 3 The evaluation of seven non-invasive models by receiver operating characteristic curves. A: The receiver operating characteristic curves (ROC) of the overall population; B: The ROC of the subgroup population. FAST: FibroScan-aspartate transaminase; FIB-4: Fibrosis-4; APRI: Aspartate transaminase to platelet ratio index; ARR: Aspartate transaminase to alanine transaminase ratio; GPR: Gamma-glutamyl transpeptidase to platelet ratio.